Pharmafile Logo
Pharmafocus logo
Advanced Search

Lucentis

Showing 15 posts of 54 posts found.

Lucentis image

Lucentis and Avastin equal in efficacy

July 19, 2013
Research and Development, Sales and Marketing Lucentis, Novartis, Roche, avastin

Latest results released this morning from a UK government trial show that off-label use of Roche’s Avastin is just as …

News
lucentis

New price and data changes NICE view on Lucentis

January 4, 2013
Sales and Marketing Bayer, Eylea, Lucentis, NICE, Novartis

A new lower price and new data analysis has persuaded NICE to recommend Lucentis for patients with diabetic macular oedema …

News
Eylea image

Eylea approval for wet AMD

November 29, 2012
Sales and Marketing Bayer, Eylea, Lucentis, Novartis, avastin, wet AMD

Bayer HealthCare’s Eylea has been appoved in Europe for the treatment of neovascular age-related macular degeneration (wet AMD). The eye …

News
ABPI image

ABPI slams NHS findings

October 18, 2012
Sales and Marketing ABPI, Lucentis, NICE, UK

The ABPI has expressed concern at a report by the NHS’s Health and Social Care Information Centre (HSCIC) which suggests …

News
Lucentis image

NICE does Lucentis U-turn

October 5, 2012
Sales and Marketing Lucentis, NICE, Novartis, Roche, avastin

NICE has done a U-turn over its previous verdict on Novartis’ Lucentis, now recommending the drug in draft guidance to …

News

Novartis to file for new Lucentis indication

September 7, 2012
Lucentis, Novartis, macular edema, macular oedema, ophthamology

Novartis is set to file eye treatment Lucentis for a new indication. The firm will submit Lucentis (ranibizumab) to the …

News
novartis_window

New Avastin data could be bad news for Lucentis

August 14, 2012
Research and Development, Sales and Marketing DMO, Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

The day after Novartis gained a new US licence for Lucentis to treat diabetic macular oedema, new data was published …

News
Lucentis image

Lucentis gains new licence in the US

August 13, 2012
Sales and Marketing Eylea, FDA, Lucentis, approval, avastin, wet AMD

Roche’s eye drug Lucentis has gained a new licence in the US to treat diabetic macular oedema. The FDA has …

News
Rawlins image

Sue NHS to ensure access to drugs, says NICE chief

August 6, 2012
Lucentis, NICE, Ozurdex, judicial review, market access, ophthamology

 The chairman of NICE is advising campaigners to sue NHS bodies that block a treatment recommended by the watchdog.In a …

News
Lucentis image

Novartis ponders Lucentis price cut in UK

May 8, 2012
Medical Communications, Sales and Marketing Lucentis, NICE, avastin, market access

 Novartis could cut the price of its eye drug Lucentis in the UK to head off moves to switch patients …

News
screen_shot_2012-04-27_at_10

Novartis right to challenge NHS on Avastin use – ABPI chief

April 27, 2012
Sales and Marketing ABPI, Lucentis, Whitehead, avastin, wet AMD

The ABPI has declared its support for Novartis in its legal challenge against off-label prescribing in England.The pharma company is …

News

GMC won’t relax off-label prescribing guidelines

April 25, 2012
Sales and Marketing GMC, Lucentis, Novartis, Roche, avastin, off label, off-label

The GMC has decided not to relax guidelines on off-label prescribing when a licensed alternative exists. The GMC’s current rules …

News
Lucentis image

Charity challenges government on Avastin for wet AMD

April 24, 2012
Sales and Marketing Lucentis, Novartis, Roche, avastin, off label, off-label, wet AMD

A leading patient group has called on the government to get to grips with the issue of off-label prescribing, as …

News

GMC guidance on off-label drug use delayed

March 19, 2012
Sales and Marketing GMC, Lucentis, avastin, off label, off-label, prescribing

The General Medical Council has delayed the release of new guidance for off-label prescribing. The doctors’ regulator was expected to …

News

Bayer eye drug succeeds in long-term study

February 21, 2012
Research and Development, Sales and Marketing Bayer, Lucentis, aflibercept, wet AMD

Bayer’s eye drug aflibercept has succeeded in a long-term study in patients with a common eye condition.  The Phase III …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026